These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 15111352)

  • 1. Survival in nephroblastoma treated according to the trial and study SIOP-9/GPOH with respect to relapse and morbidity.
    Weirich A; Ludwig R; Graf N; Abel U; Leuschner I; Vujanic GM; Mehls O; Boos J; Beck J; Royer-Pokora B; Voûte PA
    Ann Oncol; 2004 May; 15(5):808-20. PubMed ID: 15111352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical impact of histologic subtypes in localized non-anaplastic nephroblastoma treated according to the trial and study SIOP-9/GPOH.
    Weirich A; Leuschner I; Harms D; Vujanic GM; Tröger J; Abel U; Graf N; Schmidt D; Ludwig R; Voûte PA
    Ann Oncol; 2001 Mar; 12(3):311-9. PubMed ID: 11332141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Results of the SIOP 93-01/GPOH trial and study for the treatment of patients with unilateral nonmetastatic Wilms Tumor.
    Reinhard H; Semler O; Bürger D; Bode U; Flentje M; Göbel U; Gutjahr P; Leuschner I; Maass E; Niggli F; Scheel-Walter HG; Stöckle M; Thüroff JW; Tröger J; Weirich A; von Schweinitz D; Zoubek A; Graf N
    Klin Padiatr; 2004; 216(3):132-40. PubMed ID: 15175957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High dose consolidation with autologous stem cell rescue (ASCR) for nephroblastoma initially treated according to the SIOP 9/GPOH trial and study.
    Hempel L; Kremens B; Weirich A; Graf N; Zintl F; Ludwig R
    Klin Padiatr; 1996; 208(4):186-9. PubMed ID: 8776705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is radiotherapy required in first-line treatment of stage I diffuse anaplastic Wilms tumor? A report of SIOP-RTSG, AIEOP, JWiTS, and UKCCSG.
    Fajardo RD; van den Heuvel-Eibrink MM; van Tinteren H; Spreafico F; Acha T; Bergeron C; de Camargo B; Oldenburger F; Rübe C; Oue T; Vokuhl C; de Krijger RR; Vujanic G; Sebire N; Coulomb-L'Hermine A; Collini P; Gandola L; Pritchard-Jones K; Graf N; Janssens GO; van Grotel M
    Pediatr Blood Cancer; 2020 Feb; 67(2):e28039. PubMed ID: 31625685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characteristics and outcomes of preoperatively treated patients with anaplastic Wilms tumors registered in the UK SIOP-WT-2001 and IMPORT study cohorts (2002-2020).
    Vujanić GM; Mifsud W; Chowdhury T; Al-Saadi R; Pritchard-Jones K;
    Cancer; 2022 Apr; 128(8):1666-1675. PubMed ID: 35119702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of histopathological response to preoperative chemotherapy in unilateral Wilms' tumor: An analysis of 899 patients treated on the SIOP WT 2001 protocol in the UK-CCLG and GPOH studies.
    Vujanić GM; D'Hooghe E; Graf N; Vokuhl C; Al-Saadi R; Chowdhury T; Pritchard-Jones K; Furtwängler R
    Int J Cancer; 2021 Sep; 149(6):1332-1340. PubMed ID: 34109628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of children with stages II to IV anaplastic Wilms' tumor: a report from the National Wilms' Tumor Study Group.
    Green DM; Beckwith JB; Breslow NE; Faria P; Moksness J; Finklestein JZ; Grundy P; Thomas PR; Kim T; Shochat S
    J Clin Oncol; 1994 Oct; 12(10):2126-31. PubMed ID: 7931483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abdominal irradiation in unilateral nephroblastoma and its impact on local control and survival.
    Flentje M; Weirich A; Graf N; Pötter R; Zimmerman H; Ludwig R
    Int J Radiat Oncol Biol Phys; 1998 Jan; 40(1):163-9. PubMed ID: 9422573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcome of patients with stage IV high-risk Wilms tumour treated according to the SIOP2001 protocol: A report of the SIOP Renal Tumour Study Group.
    Pasqualini C; Furtwängler R; van Tinteren H; Teixeira RAP; Acha T; Howell L; Vujanic G; Godzinski J; Melchior P; Smets AM; Coulomb-L'Hermine A; Brisse H; Pritchard-Jones K; Bergeron C; de Camargo B; van den Heuvel-Eibrink MM; Graf N; Verschuur AC
    Eur J Cancer; 2020 Mar; 128():38-46. PubMed ID: 32109849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relapse of unilateral favorable histology Wilms' tumor: significant clinicopathological factors.
    Aoba T; Urushihara N; Fukumoto K; Furuta S; Fukuzawa H; Mitsunaga M; Watanabe K; Yamoto M; Miyake H; Koyama M; Iwabuchi H; Koike J; Tatsunami S; Wakisaka M; Kitagawa H
    J Pediatr Surg; 2012 Dec; 47(12):2210-5. PubMed ID: 23217878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of the Sixth International Society of Pediatric Oncology Wilms' Tumor Trial and Study: a risk-adapted therapeutic approach in Wilms' tumor.
    Tournade MF; Com-Nougué C; Voûte PA; Lemerle J; de Kraker J; Delemarre JF; Burgers M; Habrand JL; Moorman CG; Bürger D
    J Clin Oncol; 1993 Jun; 11(6):1014-23. PubMed ID: 8388918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose melphalan, etoposide, and carboplatin followed by autologous stem-cell rescue in pediatric high-risk recurrent Wilms' tumor: a French Society of Pediatric Oncology study.
    Pein F; Michon J; Valteau-Couanet D; Quintana E; Frappaz D; Vannier JP; Philip T; Bergeron C; Baranzelli MC; Thyss A; Stephan JL; Boutard P; Gentet JC; Zucker JM; Tournade MF; Hartmann O
    J Clin Oncol; 1998 Oct; 16(10):3295-301. PubMed ID: 9779704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of anaplastic histology Wilms' tumor: results from the fifth National Wilms' Tumor Study.
    Dome JS; Cotton CA; Perlman EJ; Breslow NE; Kalapurakal JA; Ritchey ML; Grundy PE; Malogolowkin M; Beckwith JB; Shamberger RC; Haase GM; Coppes MJ; Coccia P; Kletzel M; Weetman RM; Donaldson M; Macklis RM; Green DM
    J Clin Oncol; 2006 May; 24(15):2352-8. PubMed ID: 16710034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New definitions of focal and diffuse anaplasia in Wilms tumor: the International Society of Paediatric Oncology (SIOP) experience.
    Vujanić GM; Harms D; Sandstedt B; Weirich A; de Kraker J; Delemarre JF
    Med Pediatr Oncol; 1999 May; 32(5):317-23. PubMed ID: 10219330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of nuclear unrest and p53 immunostaining in Wilms' tumor.
    Salama A; Kamel A
    J Egypt Natl Canc Inst; 2011 Mar; 23(1):31-9. PubMed ID: 22099934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A 23-year experience with malignant renal tumors in infancy and childhood.
    Tröbs RB; Hänsel M; Friedrich T; Bennek J
    Eur J Pediatr Surg; 2001 Apr; 11(2):92-8. PubMed ID: 11371043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management and outcome of pediatric metastatic Wilms' tumor at the National Cancer Institute, Egypt.
    Elayadi M; Magdy S; Khalil E; Zekri W
    J Egypt Natl Canc Inst; 2020 Apr; 32(1):19. PubMed ID: 32372204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Minichromosome maintenance 2 (MCM2) is a new prognostic proliferative marker in Wilms tumour.
    Taran K; Sitkiewicz A; Andrzejewska E; Kobos J
    Pol J Pathol; 2011; 62(2):84-8. PubMed ID: 21866463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Wilms' tumor in adults: results of the Society of Pediatric Oncology (SIOP) 93-01/Society for Pediatric Oncology and Hematology (GPOH) Study.
    Reinhard H; Aliani S; Ruebe C; Stöckle M; Leuschner I; Graf N
    J Clin Oncol; 2004 Nov; 22(22):4500-6. PubMed ID: 15542800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.